Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMFORT-II: Ruxolitinib vs Best Available Therapy in Myelofibrosis
NCT00934544Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF) (2 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48. Started Jul 2009; status: completed.
02
Drugs
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT00934544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00934544.